论文部分内容阅读
Menogaril(7R-O-methylnogarol)是一种半合成的蒽环类抗生素,与阿霉素的主要不同点在于其糖部分在D环而不是在A环,其心脏毒性小于阿霉素,它浓集于细胞浆且抑制微管的聚合作用,破坏DNA链,抑制RNA的合成。协作组对确诊的47例急性髓细胞白血病(AML)患者(其中27例为首次复发,20例为第二次复发或难治性患者)施行Menogaril治疗,100mg/m~2·d,静脉滴注90分钟,连续5日。完全缓解率(CR)为17％(8/47),1例为部分缓解(PR)。总有效率为19％。8例CR病例中有7例为首次复发,占首次复发病例的26％(7/27)。第二次复发及难治的病例仅1例CR,占5％(1/20)。首次复发缓解的病例中位缓解期为6个月。
Menogaril (7R-O-methylnogarol) is a semi-synthetic anthracycline antibiotic. Its major difference from doxorubicin is that its sugar moiety is in the D ring but not in the A ring, and its cardiotoxicity is less than that of doxorubicin. Collects in the cytoplasm and inhibits the polymerization of microtubules, destroys DNA strands, and inhibits RNA synthesis. The cohort conducted Manogaril treatment in 47 patients with confirmed acute myeloid leukemia (AML) (27 of whom were relapsed for the first time and 20 of whom were second relapsed or refractory patients), 100 mg/m~2·day, intravenous drip Note 90 minutes for 5 consecutive days. The complete remission rate (CR) was 17% (8/47) and 1 case was partial remission (PR). The total effective rate is 19%. Seven of the eight CR cases were relapsed for the first time, accounting for 26% of the first relapse cases (7/27). In the second relapsed and refractory case, only one case of CR accounted for 5% (1/20). The median remission period for the first relapse remission was 6 months.